Home・Akciju saraksts・Travere Therapeutics Inc

Travere Therapeutics Inc

Slēgts

61.32 -1.72

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

60.79

Max

61.47

Galvenie mērījumi
By Trading Economics
Ienākumi	-15M -37M
Pārdošana	-2.5M 127M
EPS	0.05
Peļņas marža	-28.775
Darbinieki	497
EBITDA	-8.6M -9.2M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+17.82% upside

Dividendes
By Acuity
Nākamie ieņēmumi	2026. g. 29. okt.

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	1.3B 5.1B
Iepriekšējā atvēršanas cena	63.04
Iepriekšējā slēgšanas cena	61.32

Travere Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 8. aug. 23:51 UTC

U.S. Labor Market Contraction Fuels Stock Market Rally and Eases Fed Rate Hike Expectations

2026. g. 8. aug. 23:51 UTC

U.S. equity markets surge to record highs as July job data signals potential pause in Federal Reserve interest rate hikes, while European stocks also reach all-time highs amid mixed economic signals.

2026. g. 8. aug. 23:51 UTC

U.S. equity markets surge to record highs as disappointing July employment data shifts investor sentiment towards a potential pause in Federal Reserve interest rate hikes.

2026. g. 8. aug. 23:51 UTC

U.S. equity markets surge as disappointing July jobs data lowers Fed rate hike expectations, with S&P500 hitting record high.

2026. g. 8. aug. 23:51 UTC

US Producer Price Inflation Expected to Rise 0.1% in July Amid Labor Market Concerns and Fed Rate Speculations

2026. g. 8. aug. 23:51 UTC

Correlated Moves

Macro News

Bitcoin trades higher as a surprising jobs report fuels speculation of interest rate cuts, potentially benefiting cryptocurrencies. Ethereum also sees a slight price increase.

2026. g. 8. aug. 23:41 UTC

Core PPI Release on August 13, 2026, Expected to Show Moderate Inflation Increase Amid Mixed Labor Market Signals and Cautious Investor Sentiment.

2026. g. 8. aug. 23:31 UTC

BoJ's Upcoming Summary of Opinions on August 9, 2026, May Signal Cautious Monetary Policy Amidst Mixed Market Sentiment and Global Rate Hike Discussions.

2026. g. 8. aug. 23:21 UTC

Core Inflation Rate Expected at 2.5% Amid Mixed Economic Data and Job Losses, Influencing Fed's Interest Rate Decisions

2026. g. 8. aug. 23:21 UTC

Core Inflation Rate Release on August 12, 2026 Expected to Show +0.2% Increase Amid Mixed Economic Signals and Job Market Concerns

2026. g. 8. aug. 23:21 UTC

Investors Brace for July CPI Release Amid Mixed Employment Reports and Inflation Concerns Impacting Fed Policy Decisions

2026. g. 8. aug. 23:21 UTC

U.S. Inflation Rate Expected to Rise 0.1% in July Amid Mixed Economic Signals and Labor Market Concerns

2026. g. 8. aug. 23:21 UTC

US CPI YoY Inflation Rate Expected at 3.4% Amid Mixed Economic Signals and Job Losses, Influencing Fed's Interest Rate Decisions

2026. g. 8. aug. 23:21 UTC

Investors Brace for Volatility Ahead of August CPI Release Amid Mixed Economic Signals and Fed Rate Speculation

2026. g. 8. aug. 23:11 UTC

Brazil's Retail Sales Report on August 13 Expected to Reveal Consumer Spending Trends Amid Economic Uncertainties.

2026. g. 8. aug. 22:41 UTC

U.S. 30-Year Mortgage Rates Hit Year-High of 6.81% Amid Weak Job Growth and Fed Rate Speculation

2026. g. 8. aug. 22:41 UTC

Cardano is trading lower today, continuing a downward trend since Friday. The asset remains above its 20-day moving average and near its one-month range high.

2026. g. 8. aug. 22:31 UTC

Brazil's Inflation Rate MoM Release on August 11, 2026, Sparks Caution Among Analysts Amid Global Economic Uncertainties.

2026. g. 8. aug. 22:31 UTC

Brazil's Inflation Rate Release on August 11, 2026 Expected to Reflect Moderate Trends Amid Global Economic Concerns.

2026. g. 8. aug. 22:11 UTC

UK Housing Market Faces Caution Ahead of RICS House Price Balance Release Amid Stagnant Prices and Economic Uncertainty

2026. g. 8. aug. 21:51 UTC

Japan's Current Account Surplus Forecasted at JPY 1,512 Billion Amid Forex Interventions and Cautious Market Sentiment Ahead of August Release.

2026. g. 8. aug. 21:41 UTC

South Korea's unemployment rate expected to hold steady at 2.7% amid global economic uncertainties, with market sentiment cautiously optimistic ahead of August release.

2026. g. 8. aug. 21:31 UTC

UK Retail Sales Monitor YoY for July 2026 Expected to Rise 1.5% Amid Mixed Sentiment and Economic Pressures

2026. g. 8. aug. 21:21 UTC

India's July 2026 Inflation Rate Release Expected to Show Stability at 4.54% Amid Geopolitical Tensions and Food Price Pressures

2026. g. 8. aug. 21:21 UTC

Brazil's Central Bank to announce interest rate decisions amid global economic uncertainties on August 10, 2026.

2026. g. 8. aug. 20:31 UTC

Euro Area's Q2 Employment Change Data Release on August 14 Sparks Cautious Optimism Amid Rising Unemployment and Mixed Economic Signals.

2026. g. 8. aug. 20:31 UTC

Euro Area Expected to Report €2.2 Billion Trade Deficit Amid Mixed Economic Signals and Rising Energy Costs

2026. g. 8. aug. 20:31 UTC

China's Q2 2026 Current Account Data Release Expected to Show Continued Surplus Growth Amidst Global Economic Pressures

2026. g. 8. aug. 20:11 UTC

Eurozone Industrial Production MoM data for June 2026 expected to show flat growth amid concerns over declining output and geopolitical tensions.

2026. g. 8. aug. 20:01 UTC

South Africa's Q2 Unemployment Rate Set for Release Amidst Rising Global Job Concerns, Following Alarming 32.7% in Q1

Salīdzinājums

Cenas izmaiņa

Travere Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

17.82% augšup

Prognoze 12 mēnešiem

Vidējais 72.25 USD 17.82%

Augstākais 90 USD

Zemākais 49 USD

Pamatojoties uz 12 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Travere Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

12 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 12 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Travere Therapeutics Inc — pēdējo 3 mēnešu laikā.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Travere Therapeutics Inc

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.